Treatment of DSS colitis mice with the AP-Cav peptide resulted in reduced disease activity index, reduced histopathology score, and decreased angiogenesis, suggesting that AP-Cav has the potential to treat colitis [1]. This evidence concerns the gene CAV1 and colitis.